Infection with chronic hepatitis B (CHB) is a major public health problem in China and other Asian countries. This was the first paper to examine the influence of disease and healthcare requirements on the healthrelated quality of life (HRQOL) of Chinese CHB patients at various stages of illness. Using the Chronic Liver Disease Questionnaire (CLDQ), a liver disease specific HRQOL instrument, and the Chinese (HK) Short Form-36 Health Survey version 2 (SF-36v2), a complete assessment of the HRQOL and health preferences of Chinese patients with various stages of CHB was made. Specifically, researchers looked at how CHB patients' treatment demands and use correlated with HRQOL. Iterative translations, expert panel review, and cognitive debriefing were used to make the Chronic Liver Disease Questionnaire (CLDQ) accessible to the Chinese community in Hong Kong. The validity, reliability, and sensitivity of the test were demonstrated in a small pilot research including 150 CHB patients. Patients with various stages of CHB illness, including asymptomatic liver function and impaired liver function, cirrhosis and hepato cellular carcinoma, were assessed for their HRQOL using the Chinese (HK) CLDQ and the Chinese (HK) SF-36v2, a general HRQOL measure (HCC). HRQOL ratings were considerably lower in AHB carriers than in the general population. These preference values were translated from SF-36v2 to Short Form-6D (SF-6D) and showed a gradual decline from 0.755 in AHB to 0.745 in ILF, 0.720 in HCC and 0.701 in cirrhosis compared to the 0.787 population norm for each group. Taking antiviral medication, higher bilirubin levels, psychiatric co-morbidity, younger age, and female gender were all linked to worse HRQOL despite the fact that CHB disease severity (stage) was not included.